In recent events, India has lifted its previously imposed ban on the export of Hydroxychloroquine (HCQ), a medication primarily used to treat malaria that has been in use for COVID-19 treatment.
Response to U.S. Pressure
The decision to lift the ban came after the U.S. President indicated that retaliatory action could be expected if India continued to withhold HCQ supplies. Previously, the Indian government had listed HCQ as a restricted item and later imposed a comprehensive ban on all its exports.
India’s Stand on the Issue
Lifting the ban is an act designated towards addressing the humanitarian aspects of the global pandemic.
Assisting Neighbouring Countries
India has agreed to issue licenses for paracetamol and HCQ in appropriate quantities for all neighbouring countries that depend on India’s capabilities. Additionally, it plans to supply these essential medications to countries experiencing significant distress due to the pandemic.
Fulfilment of Pre-existing Orders
The Indian government plans to meet the pre-existing orders, predominantly to the U.S., Brazil, and various European nations since they have already made advance payments.
Balancing Domestic Demand and Exports
Exported orders will be fulfilled based on stock availability and domestic demand for the medication, which would undergo continuous monitoring. The Indian government has confirmed that it currently possesses an adequate stock of HCQ.
Insights into Hydroxychloroquine
Hydroxychloroquine is an orally administered drug typically used to treat malaria and some autoimmune diseases, including rheumatoid arthritis. Malaria spreads through female Anopheles mosquito bites carrying parasites. Autoimmune diseases, where the body’s immune system attacks healthy cells, includes rheumatoid arthritis, chronic inflammatory disorder affecting numerous joints.
Hydroxychloroquine as a Potential Weapon against COVID-19
Recent studies hint that the HCQ medication, alone or when paired with azithromycin, appears to reduce virus concentration quickly. Evidence suggests that prophylactic treatment with HCQ may deter SARS-CoV-2 infection at approved doses. However, potential side effects exist, including cardiac arrhythmia and liver damage. Overuse could also limit people’s ability to fight off the disease.
The series of events underlines India’s strategic role in the global healthcare landscape, particularly in responding to significant health crises such as COVID-19. The export of HCQ has been seen as a balancing act between domestic needs and international demands, showcasing India’s commitment to global welfare.
Last Modified: February 7, 2024